This report provides information on the therapeutic development for Urinary Tract Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Tract Cancer. 'Urinary Tract Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of the Research

- A snapshot of the global therapeutic scenario for Urinary Tract Cancer.
- A review of the Urinary Tract Cancer products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Urinary Tract Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Identify and understand important and diverse types of therapeutics under development for Urinary Tract Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Urinary Tract Cancer pipeline depth and focus of Urinary Tract Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 13
Introduction 14
Global March kets Direct Report Coverage 14
Urinary Tract Cancer Overview 15
Therapeutics Development 16
An Overview of Pipeline Products for Urinary Tract Cancer 16
Urinary Tract Cancer Therapeutics under Development by Firms 18
Urinary Tract Cancer Therapeutics under Investigation by Universities/Institutes 28
Late Stage Products 41
Comparative Analysis 41
Mid Clinical Stage Products 42
Comparative Analysis 42
Early Clinical Stage Products 43
Comparative Analysis 43
Discovery and Pre-Clinical Stage Products 44
Comparative Analysis 44
Urinary Tract Cancer Therapeutics - Products under Development by Firms 45
Urinary Tract Cancer Therapeutics - Products under Investigation by Universities/Institutes 58
Companies Involved in Urinary Tract Cancer Therapeutics Development 91
Bristol-Myers Squibb Firms 91
Genzyme Corporation 92
Boehringer Ingelheim GmbH 93
F. Hoffmann-La Roche Ltd. 94
Kyowa Hakko Kirin Co., Ltd. 95
Shionogi and Co., Ltd. 96
Amgen Inc. 97
Medical Enzymes AG 194
IkerChem S.L. 195
Immunovative Therapies, Ltd. 196
Urinary Tract Cancer - Therapeutics Assessment 197
Assessment by Monotherapy Products 197
Assessment by Combination Products 198
Assessment by Route of Administration 199
Assessment by Molecule Type 202
Drug Profiles 205
Nexavar - Drug Profile 205
Axitinib - Drug Profile 207
Axitinib - Drug Profile 209
Sutent - Drug Profile 211
Sotatercept - Drug Profile 213
ANYARA - Drug Profile 215
IMA901 - Drug Profile 216
TroVax - Drug Profile 217
NuLeusin - Drug Profile 219
Urocidin - Drug Profile 220
Eoquin - Drug Profile 221
Tivozanib - Drug Profile 223
Rencarex - Drug Profile 225
Dovitinib - Drug Profile 227
Selenium + Vitamin E - Drug Profile 229
Celecoxib - Drug Profile 230
Methotrexate + Cisplatin - Drug Profile 232
Aldesleukin for Kidney Cancer - Drug Profile 233
Aldesleukin + Recombinant interferon alfa + Fluorouracil - Drug Profile 234
Bevacizumab + Torisel - Drug Profile 236
Gemcitabine + Cisplatin + Bevacizumab - Drug Profile 237
Interferon Alfa-2B + Bevacizumab - Drug Profile 238
Interferon Alfa-2B - Drug Profile 239
BAY43-9006 - Drug Profile 240
Sunitinib - Drug Profile 242
Uracil-Tegafur - Drug Profile 243
Gemcitabine - Drug Profile 244
Javlor - Drug Profile 246
Fenretinide - Drug Profile 248
Methotrexate + Vinblastine + Doxorubicin + Cisplatin - Drug Profile 249
Cisplatin + Adriamycin + Methotrexate + Vinblastine - Drug Profile 251
Dactinomycin + Doxorubicin + Vincristine - Drug Profile 253
Sorafenib Tosylate - Drug Profile 254
Larotaxel + Cisplatin - Drug Profile 255
Recombinant Interferon Alfa + Isotretinoin - Drug Profile 257
Interferon Alfa + CCI-779 - Drug Profile 258
BCG Vaccine + Iressa - Drug Profile 259
Fluorouracil + Mitomycin C + Radiation Therapy - Drug Profile 260
Interleukin-2 - Drug Profile 261
Dactinomycin + Filgrastim + Cylophosphamide + Doxorubicin hydrochloride + Etoposide + Vincristine sulfate + Radiation therapy - Drug Profile 262
RAD001 - Drug Profile 265
TroVax + IL-2 - Drug Profile 267
Interferon-Alpha + Interleukin-2 + 5-Fluorouracil - Drug Profile 269
Filgrastim + Doxorubicin + Ifosfamide - Drug Profile 271
Mitomycin C - Drug Profile 273
Interferon-Alpha - Drug Profile 274
Mitomycin + Hyperthermia Therapy - Drug Profile 275
Cisplatin + Cyclophosphamide + Adriamycin - Drug Profile 276
Votrient - Drug Profile 277
Everolimus + Bevacizumab - Drug Profile 279
ANYARA + Interferon Alpha - Drug Profile 280
Sunitinib - Drug Profile 281
Interferon-alpha - Drug Profile 282
MVAC Therapy - Drug Profile 283
BCG Therapy - Drug Profile 285
Interleukin 2 + Interferon-alpha2 - Drug Profile 286
Dactinomycine + Doxorubicin + Vincristine + Radiation Therapy - Drug Profile 287
Cisplatin + Radiation Therapy - Drug Profile 288
Mitomycin C - Drug Profile 289
Sorafenib - Drug Profile 290
Sorafenib + Sunitinib - Drug Profile 291
bevacizumab + recombinant interferon alfa - Drug Profile 292
Carboplatin + Methotrexate + Vinblastine - Drug Profile 293
Cisplatin + Doxorubicin + Gemcitabine + Methotrexate + Vinblastine + Filgrastim - Drug Profile 295
aldesleukin + recombinant interferon alfa + fluorouracil - Drug Profile 297
Dactinomycin + Carboplatin + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Vincristine Sulfate - Drug Profile 299
Doxorubicin hydrochloride - Drug Profile 302
Gemcitabine + Cisplatin - Drug Profile 303
Sunitinib - Drug Profile 305
Recombinant Gamma Interferon - Drug Profile 306
Methotrexate - Drug Profile 307
Thiotepa - Drug Profile 308
Bacillus Calmette-Guerin Vaccine - Drug Profile 309
Cisplatin + Radiation Therapy - Drug Profile 311
Pirarubicin - Drug Profile 312
Sunitinib - Drug Profile 313
Bevacizumab + Interferon Alfa-2a - Drug Profile 314
Urinary Tract Cancer Therapeutics - Drug Profile Updates 315
Urinary Tract Cancer Therapeutics - Discontinued Products 323
Urinary Tract Cancer Therapeutics - Dormant Products 329
Urinary Tract Cancer - Product Development Milestones 359
Featured News and Press Releases 359
Appendix 368
Methodology 368
Expert Panel Validation 369
Contact Us 369
Disclaimer 369

List of Tables

Number of Products Under Development for Urinary Tract Cancer, H1 2012 21
Products under Development for Urinary Tract Cancer - Comparative Analysis, H1 2012 22
Number of Products under Development by Firms, H1 2012 24
Number of Products under Investigation by Universities/Institutes, H1 2012 34
Comparative Analysis by Late Stage Development, H1 2012 46
Comparative Analysis by Mid Clinical Stage Development, H1 2012 47
Comparative Analysis by Early Clinical Stage Development, H1 2012 48
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 49
Products under Development by Firms, H1 2012 50
Products under Investigation by Universities/Institutes, H1 2012 63
Bristol-Myers Squibb Firms, H1 2012 96
Genzyme Corporation, H1 2012 97
Boehringer Ingelheim GmbH, H1 2012 98
F. Hoffmann-La Roche Ltd., H1 2012 99
Kyowa Hakko Kirin Co., Ltd., H1 2012 100
Shionogi and Co., Ltd., H1 2012 101
Amgen Inc., H1 2012 102
Sanofi-Aventis, H1 2012 103
AstraZeneca PLC, H1 2012 104
Eli Lilly and Firms, H1 2012 105
GlaxoSmithKline plc, H1 2012 106
Seattle Genetics, Inc., H1 2012 107
Bioniche Life Sciences, Inc., H1 2012 108
Genentech, Inc., H1 2012 109
Merck and Co., Inc., H1 2012 110
Emergent BioSolutions Inc., H1 2012 111
Oxford BioMedica plc, H1 2012 112
Light Sciences Oncology, Inc., H1 2012 113
November artis AG, H1 2012 114
ImClone Systems Incorporated, H1 2012 115
Astellas Pharma Inc., H1 2012 116
Eisai Co., Ltd., H1 2012 117
Genta Incorporated, H1 2012 118
MDRNA, Inc., H1 2012 119
Ono Pharmaceutical Co., Ltd., H1 2012 120
OSI Pharmaceuticals, Inc., H1 2012 121
Pfizer Inc., H1 2012 122
Taiho Pharmaceutical Co., Ltd., H1 2012 123
Exelixis, Inc., H1 2012 124
Alfacell Corporation, H1 2012 125
Celgene Corporation, H1 2012 126
Bayer AG, H1 2012 127
MannKind Corporation, H1 2012 128
Halozyme Therapeutics, H1 2012 129
3SBio Inc., H1 2012 130
EntreMed, Inc., H1 2012 131
Celldex Therapeutics, Inc., H1 2012 132
Active Biotech AB, H1 2012 133
AEterna Zentaris Inc., H1 2012 134
AIDA Pharmaceuticals, Inc., H1 2012 135
Lorus Therapeutics Inc, H1 2012 136
Bionomics Limited, H1 2012 137
Northwest Biotherapeutics, Inc., H1 2012 138
Cleveland BioLabs, Inc., H1 2012 139
Oncolytics Biotech Inc., H1 2012 140
Patrys Limited, H1 2012 141
Keryx Biopharmaceuticals, Inc., H1 2012 142
ARQULE, INC, H1 2012 143
Allos Therapeutics, Inc, H1 2012 144
Flamel Technologies S.A., H1 2012 145
TopoTarget A/S, H1 2012 146
Oncogenex Pharmaceuticals, Inc., H1 2012 147
Dendreon Corporation, H1 2012 148
Sanochemia Pharmazeutika AG, H1 2012 149
Green Cross Corporation, H1 2012 150
MOLOGEN AG, H1 2012 151
OncoTherapy Science, Inc., H1 2012 152
Threshold Pharmaceuticals, Inc., H1 2012 153
Innate Pharma SA, H1 2012 154
Protox Therapeutics Inc., H1 2012 155
Rexahn Pharmaceuticals, Inc., H1 2012 156
PCI Biotech Holding ASA, H1 2012 157
Spectrum Pharmaceuticals, Inc., H1 2012 158
Debiopharm Group, H1 2012 159
Antisense Pharma GmbH, H1 2012 160
Wilex AG, H1 2012 161
Philogen S.p.A., H1 2012 162
Acceleron Pharma, Inc., H1 2012 163
Med Discovery SA, H1 2012 164
Cadila Pharmaceuticals Ltd., H1 2012 165
ERYtech Pharma, H1 2012 166
immatics biotechnologies GmbH, H1 2012 167
Curacyte AG, H1 2012 168
Argos Therapeutics, Inc., H1 2012 169
Cytheris SA, H1 2012 170
Altor BioScience Corporation, H1 2012 171
AgrenVec, S.L., H1 2012 172
Alethia Biotherapeutics Inc., H1 2012 173
Telormedix SA, H1 2012 174
Gene Signal International SA., H1 2012 175
MacroGenics, Inc., H1 2012 176
Pivotal BioSciences, Inc., H1 2012 177
Neotropix, Inc., H1 2012 178
Jennerex Biotherapeutics, Inc., H1 2012 179
Stemline Therapeutics, Inc., H1 2012 180
BioCancell Therapeutics, Inc., H1 2012 181
Endocyte, Inc., H1 2012 182
Polyphenon Pharma, H1 2012 183
Advenchen Laboratories, LLC, H1 2012 184
AndroScience Corporation, H1 2012 185
Immutep S.A., H1 2012 186
Syndax Pharmaceuticals, Inc., H1 2012 187
Esperance Pharmaceuticals, Inc., H1 2012 188
Welichem Biotech Inc., H1 2012 189
PharmaMarch, S.A., H1 2012 190
Tigris Pharmaceuticals, Inc., H1 2012 191
Viventia Biotechnologies Inc., H1 2012 192
AVEO Pharmaceuticals, Inc., H1 2012 193
TRACON Pharmaceuticals, Inc., H1 2012 194
KAHR medical Ltd., H1 2012 195
Advanced Cancer Therapeutics, H1 2012 196
Targa Therapeutics Corp., H1 2012 197
Cytavis Biopharma GmbH, H1 2012 198
Medical Enzymes AG, H1 2012 199
IkerChem S.L., H1 2012 200
Immunovative Therapies, Ltd., H1 2012 201
Assessment by Monotherapy Products, H1 2012 202
Assessment by Combination Products, H1 2012 203
Assessment by Stage and Route of Administration, H1 2012 206
Assessment by Molecule Type, H1 2012 209
Urinary Tract Cancer Therapeutics - Drug Profile Updates 320
Urinary Tract Cancer Therapeutics - Discontinued Products 328
Urinary Tract Cancer Therapeutics - Dormant Products 334

List of Figures

Number of Products under Development for Urinary Tract Cancer, H1 2012 21
Products under Development for Urinary Tract Cancer - Comparative Analysis, H1 2012 22
Products under Development by Firms, H1 2012 23
Products under Investigation by Universities/Institutes, H1 2012 33
Late Stage Products, H1 2012 46
Mid Clinical Stage Products, H1 2012 47
Early Clinical Stage Products, H1 2012 48
Discovery and Pre-Clinical Stage Products, H1 2012 49
Assessment by Monotherapy Products, H1 2012 202
Assessment by Combination Products, H1 2012 203
Assessment by Route of Administration, H1 2012 204
Assessment by Stage and Route of Administration, H1 2012 205
Assessment by Molecule Type, H1 2012 207
Assessment by Stage and Molecule Type, H1 2012 208

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Antibiotics: Technologies and Global Markets

Antibiotics: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Identify the major market trends and the factors driving or inhibiting the growth of the global pharmaceutical antibiotics market and its various submarkets. - Learn about developments ...

Antifungal Drugs : Technologies and Global Markets

Antifungal Drugs : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This report aims to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 through 2018. It covers approved human therapeutics ...

A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market

A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market

  • $ 5 000
  • Industry report
  • April 2014
  • by Frost & Sullivan

Prescription drug therapy for the treatment of obesity is experiencing a revival of interest with new government incentives and the recent approval of 2 new drugs, with 2 more pending imminent approval. ...

Marketview: Rsv Vaccines

May 2014 $ 4 495

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.